The UK pharma industry saw a spike in public trust and favourability amid the COVID-19 pandemic that, so far, shows little sign of wearing off, according to a new poll.
People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh